Sun-230 Cutaneous Manifestations In hemodialysis Patients

Abstract

stay, and ICU and 28-day mortality rate. We compared the characteristics of patients who survived and did not survive after 28 days and their mean arterial pressure (MAP), inotropic score, creatinine, APACHE II score, procalcitonin before and after hemoperfusion treatment. Results: The ICU mortality rate and 28-day mortality rate were 46.34% and 41.6% respectively which are lower than the predicted mortality rate of 49.70% based on the APACHE II score before hemoperfusion treatment and 54% among patients with septic shock. The mean duration of ICU stay is 23.0 AE26.66 and the mean duration of mechanical ventilation is 21.0 AE27.02. There is a significant difference between the non-survivors and the survivors in terms of duration of ICU stay (p ¼0.006), duration of mechanical ventilation (p ¼0.029), number of hemoperfusion treatments (p ¼0.007) and timing of hemoperfusion (p ¼0.006). Among the survivors, 11 (45.83%) had early hemoperfusion ( treatment has significant effect on the duration of ICU stay (p ¼ 0.008) and duration of mechanical ventilation (p ¼0.016). The result shows no significant difference in APACHE II score, inotropic score, hospital stay and renal recovery between early and late hemoperfusion (>48 h) treatment. One patient had bleeding after hemoperfusion treatment. Among the survivors and non-survivors, there was no significant reduction in platelet count before and after hemoperfusion treatment (p ¼0.179, 0.791 respectively). Other reactions such as fever and chills were not observed.Conclusions: Hemoperfusion treatment results in lower ICU and 28day mortality rate. Hemoperfusion has significant effect on the duration of ICU stay and mechanical ventilation. We recommend early hemoperfusion (within 48 hours of diagnosis of sepsis) because it is a significant factor in decreasing ICU and 28-day mortality. Early hemoperfusion treatment also has significant effect on the duration of ICU stay and mechanical ventilation. There were no serious adverse reactions reported during the duration of observation.